Skip to main
ABVX

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 62%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Abivax SA is positioned favorably in the biotechnology sector, particularly with its drug candidate obefazimod, which is currently undergoing Phase 3 clinical trials for ulcerative colitis, a chronic inflammatory disease. The expected growth of the ulcerative colitis market, projected to increase from $9.2 billion in 2025 to $21.2 billion by 2032, coupled with significant clinical data demonstrating the effectiveness of obefazimod, supports a strong outlook for the company. Furthermore, the anticipated annual sales of approximately €9.5 billion ($11 billion) by 2039 and a compound annual growth rate (CAGR) of around 7.8% underscore the potential for substantial financial returns as the global inflammatory bowel disease market expands.

Bears say

Abivax's stock outlook appears negative due to several concerning factors, primarily related to its clinical trial outcomes and competitive positioning. The company's obefazimod drug candidate has demonstrated a disappointing placebo-adjusted clinical remission rate of less than 20%, raising substantial concerns over its market potential and diminishing the interest from potential acquirers. Additionally, the limited patent protection, expiring in 2035 with hopes for an extension to 2039, along with higher clinical risks and possible negative comparisons to competitor benchmarks, suggests a perilous environment for maintaining franchise value and future growth.

Abivax SA (ABVX) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 62% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 13 analysts, Abivax SA (ABVX) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $128, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $128, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.